Compounds > 1,12-diamino-3,6,9-triazadodecane
Page last updated: 2024-11-13

1,12-diamino-3,6,9-triazadodecane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,12-diamino-3,6,9-triazadodecane: a copper-chelating agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71357122
CHEMBL ID3526694
SCHEMBL ID15226686
MeSH IDM0488153

Synonyms (6)

Synonym
211319-41-4
SCHEMBL15226686
CHEMBL3526694
n~1~-[2-({2-[(2-aminoethyl)amino]ethyl}amino)ethyl]propane-1,3-diamine
DTXSID10781212
1,12-diamino-3,6,9-triazadodecane
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1210032Drug metabolism in SSAT1-knockout mouse primary hepatocytes at 100 uM for 4 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210027Drug metabolism assessed as mouse SSAT1-mediated metabolite formation2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210025Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N1-acetyl)-1,12-diamino-3,6,9-triazadodecane formation at 100 uM for 24 hrs in presence of SSAT2 shRNA2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210020Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N12-acetyl)-1,12-diamino-3,6,9-triazadodecane formation at 100 uM for 24 hrs pretreated with 50 uM DENSpm for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210042Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N1-acetyl)-1,12-diamino-3,6,9-triazadodecane formation at 100 uM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210048Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N1-acetyl)-1,12-diamino-3,6,9-triazadodecane formation at 100 uM for 24 hrs pretreated with 50 uM DENSpm for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210033Drug metabolism in mouse primary hepatocytes assessed as SSAT1-mediated (N1-acetyl)-1,12-diamino-3,6,9-triazadodecane formation at 100 uM for 4 hrs in presence of SSAT2 siRNA2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210038Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N1-acetyl)-spermine formation at 100 uM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210024Drug metabolism in human HepG2 cells at 100 uM for 24 hrs in presence of SSAT1 shRNA2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
AID1210037Drug metabolism in human HepG2 cells assessed as SSAT1-mediated (N1-acetyl)-spermidine formation at 100 uM for 24 hrs2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and thialysine acetyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
n(1)-acetylspermidine
N(1)-acetylspermidine : An acetylspermidine having the acetyl group at the N1-position.		2.0810acetylspermidineEscherichia coli metabolite;
metabolite
n'-acetylspermine
N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).		2.0810acetamides;
acetylspermine		human metabolite
spermine
[no description available]		2.9940polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
risperidone
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.		2.11101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
trientine
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.. TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.. 2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.		2.0810polyazaalkane;
tetramine		copper chelator
ConditionIndicatedRelationship StrengthStudiesTrials
Psychoses
[description not available]		02.1110
Psychotic Disorders
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)		02.1110